Rothschild Asset Management Inc. cut its stake in Steris Plc (NYSE:STE) by 13.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 150,745 shares of the company’s stock after selling 23,417 shares during the period. Rothschild Asset Management Inc.’s holdings in Steris Plc were worth $11,019,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Janus Capital Management LLC boosted its position in Steris Plc by 28.7% in the second quarter. Janus Capital Management LLC now owns 5,022,412 shares of the company’s stock valued at $345,288,000 after buying an additional 1,120,438 shares during the period. Westfield Capital Management Co. LP boosted its position in Steris Plc by 2.2% in the second quarter. Westfield Capital Management Co. LP now owns 3,035,201 shares of the company’s stock valued at $208,670,000 after buying an additional 64,702 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Steris Plc by 7.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,963,285 shares of the company’s stock valued at $134,975,000 after buying an additional 128,956 shares during the period. Fisher Asset Management LLC boosted its position in Steris Plc by 1.0% in the third quarter. Fisher Asset Management LLC now owns 1,639,312 shares of the company’s stock valued at $119,834,000 after buying an additional 16,808 shares during the period. Finally, Frontier Capital Management Co. LLC boosted its position in Steris Plc by 0.9% in the second quarter. Frontier Capital Management Co. LLC now owns 1,602,589 shares of the company’s stock valued at $110,178,000 after buying an additional 13,596 shares during the period. Institutional investors and hedge funds own 91.50% of the company’s stock.

Institutional Ownership by Quarter for Steris Plc (NYSE:STE)

Shares of Steris Plc (NYSE:STE) opened at 68.50 on Friday. Steris Plc has a 52 week low of $61.38 and a 52 week high of $74.63. The firm’s 50-day moving average price is $67.86 and its 200 day moving average price is $69.12. The firm has a market cap of $5.84 billion, a PE ratio of 34.58 and a beta of 1.27.

Steris Plc (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported $0.89 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.90 by $0.01. Steris Plc had a return on equity of 9.89% and a net margin of 6.41%. The company earned $646.40 million during the quarter, compared to analyst estimates of $670.24 million. During the same period last year, the company posted $0.83 earnings per share. The company’s revenue was up 31.9% compared to the same quarter last year. Equities analysts anticipate that Steris Plc will post $3.89 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 21st. Stockholders of record on Wednesday, November 23rd were paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.64%. The ex-dividend date was Monday, November 21st. Steris Plc’s dividend payout ratio (DPR) is presently 57.14%.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be read at http://www.dailypolitical.com/2017/01/13/rothschild-asset-management-inc-reduces-stake-in-steris-plc-ste.html.

Several research analysts recently commented on STE shares. Zacks Investment Research upgraded Steris Plc from a “sell” rating to a “hold” rating in a research note on Monday. JMP Securities reiterated a “buy” rating on shares of Steris Plc in a research note on Friday, November 4th. Finally, Goldman Sachs Group, Inc. (The) started coverage on Steris Plc in a research note on Wednesday, November 30th. They issued a “neutral” rating and a $71.00 price target on the stock.

In other Steris Plc news, Director Cynthia L. Feldmann sold 4,744 shares of the stock in a transaction on Friday, November 4th. The shares were sold at an average price of $64.98, for a total transaction of $308,265.12. Following the transaction, the director now directly owns 14,581 shares of the company’s stock, valued at $947,473.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP John Adam Zangerle sold 3,100 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $69.00, for a total transaction of $213,900.00. Following the transaction, the vice president now directly owns 26,589 shares in the company, valued at $1,834,641. The disclosure for this sale can be found here. 2.52% of the stock is currently owned by insiders.

Steris Plc Company Profile

STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.

5 Day Chart for NYSE:STE

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris Plc (NYSE:STE).

Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.